NCT06478056 2026-02-06
VEINOPAN
University Hospital, Rouen
Phase NA Completed
Clinical Trials
9 trialsNCT04594772 2025-07-02
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT05841706 2025-06-10
Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT02757859 2025-05-20
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
Thomas Jefferson University
Phase NA Recruiting
NCT05462496 2024-10-15
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT03801915 2023-03-21
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02562716 2022-10-19
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT03891472 2019-11-13
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
Medical University of Silesia
Phase 2 Completed
NCT02117895 2016-08-11
Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail
Fudan University
Phase 3 Unknown